Jianming Xu

1992–2026 年に発表

375
論文数
63,616
被引用数
121
h 指数
339
i10 指数

被引用数

Jianming Xu の年別被引用数1979 年: 被引用 1 件1991 年: 被引用 2 件1993 年: 被引用 17 件1994 年: 被引用 41 件1995 年: 被引用 32 件1996 年: 被引用 36 件1997 年: 被引用 36 件1998 年: 被引用 49 件1999 年: 被引用 66 件2000 年: 被引用 107 件2001 年: 被引用 105 件2002 年: 被引用 135 件2003 年: 被引用 108 件2004 年: 被引用 148 件2005 年: 被引用 141 件2006 年: 被引用 129 件2007 年: 被引用 108 件2008 年: 被引用 109 件2009 年: 被引用 170 件2010 年: 被引用 179 件2011 年: 被引用 215 件2012 年: 被引用 249 件2013 年: 被引用 243 件2014 年: 被引用 340 件2015 年: 被引用 298 件2016 年: 被引用 359 件2017 年: 被引用 425 件2018 年: 被引用 473 件2019 年: 被引用 1,472 件2020 年: 被引用 1,788 件2021 年: 被引用 1,915 件2022 年: 被引用 2,038 件2023 年: 被引用 1,746 件2024 年: 被引用 2,976 件2025 年: 被引用 1,439 件2026 年: 被引用 55 件1980〜1990 年は被引用が無いため表示していません1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 6,176 件、この内訳の 28.5%アメリカ合衆国: 引用元論文 4,025 件、この内訳の 18.6%日本: 引用元論文 945 件、この内訳の 4.4%イギリス: 引用元論文 842 件、この内訳の 3.9%ドイツ: 引用元論文 801 件、この内訳の 3.7%イタリア: 引用元論文 795 件、この内訳の 3.7%フランス: 引用元論文 618 件、この内訳の 2.9%韓国: 引用元論文 602 件、この内訳の 2.8%スペイン: 引用元論文 545 件、この内訳の 2.5%カナダ: 引用元論文 433 件、この内訳の 2%オーストラリア: 引用元論文 429 件、この内訳の 2%インド: 引用元論文 421 件、この内訳の 1.9%
0%28.5%その他 23.1%

分野

  • Medicine49.4%
  • Biochemistry, Genetics and Molecular Biology23.9%
  • Environmental Science12.4%
  • Immunology and Microbiology2.6%
  • Agricultural and Biological Sciences2.4%
  • Engineering2.1%
  • その他7.2%

トピック

  • Hepatocellular Carcinoma Treatment and Prognosis5%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Gastric Cancer Management and Outcomes2.4%
  • Heavy metals in environment1.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies1.7%
  • Cancer Mechanisms and Therapy1.6%
  • その他83.9%

共著者

全論文

検索で開く
  1. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gao‐Jun Teng, Yanru Qin, Jinhai Wang, Feng Xia, Guowen Yin, Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan - The Lancet Oncology 2021 被引用: 1,115

  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2008 被引用: 5,842

  3. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 711

  4. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 1,181

  5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

    著者: , , , , , , , , , , , , , , , , , , , - Nature 2021 被引用: 709

  6. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baojin Hua, Xiaowu Huang, Weidong Jia, Yaming Li, Ye‐Xiong Li, Jun Liang, Tianshu Liu, Guoyue Lv, Yilei Mao, Tao Peng, Weixin Ren, Hongcheng Shi, Guo‐Ming Shi, Kaishan Tao, Wentao Wang, Xiaoying Wang, Zhiming Wang, Bang‐De Xiang, Baocai Xing, Jianming Xu, Jiamei Yang, Jianyong Yang, Yefa Yang, Yunke Yang, Sheng‐Long Ye, Zhengyu Yin, Bixiang Zhang, Boheng Zhang, Leida Zhang, Shuijun Zhang, Ti Zhang, Yongfu Zhao, Honggang Zheng, Jiye Zhu, Kangshun Zhu, Rong Liu, Ying–Hong Shi, Yong‐Sheng Xiao, Zhi Dai, Gao‐Jun Teng, Jianqiang Cai, Weilin Wang, Xiujun Cai, Qiang Li, Feng Shen, Shukui Qin, Jiahong Dong, Jia Fan - Liver Cancer 2020 被引用: 833

  7. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 467

  8. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Doki, Yuichiro, Ajani, Jaffer A., Kato, Ken, Xu, Jianming, Wyrwicz, Lucjan, Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih Hung, Adenis, Antoine, Di Bartolomeo, Maria, Braghiroli, Maria I., Holtved, Eva, Ostoich, Sandra A., Kim, Hye R., Ueno, Masaki, Mansoor, Wasat, Yang, Wen Chi, Liu, Tianshu, Bridgewater, John, Makino, Tomoki, Xynos, Ioannis, Liu, Xuan, Lei, Ming, Kondo, Kaoru, Patel, Apurva, Gricar, Joseph, Chau, Ian, Kitagawa, Yuko - 2022 被引用: 532

  9. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shuqun Cheng, Chaoliu Dai, Wenzhi Guo, Yabing Guo, Baojin Hua, Xiaowu Huang, Weidong Jia, Qiu Li, Tao Li, Xun Li, Yaming Li, Ye‐Xiong Li, Jun Liang, Changquan Ling, Tianshu Liu, Xiufeng Liu, Shichun Lu, Guoyue Lv, Yilei Mao, Zhiqiang Meng, Tao Peng, Weixin Ren, Hongcheng Shi, Guo‐Ming Shi, Ming Shi, Tianqiang Song, Kaishan Tao, Jianhua Wang, Kui Wang, Lu Wang, Wentao Wang, Xiaoying Wang, Zhiming Wang, Bang‐De Xiang, Baocai Xing, Jianming Xu, Jiamei Yang, Yang Jianyong, Yefa Yang, Yunke Yang, Sheng‐Long Ye, Zhen‐Yu Yin, Yong Zeng, Bixiang Zhang, Boheng Zhang, Leida Zhang, Shuijun Zhang, Ti Zhang, Yanqiao Zhang, Ming Zhao, Yongfu Zhao, Honggang Zheng, Ledu Zhou, Jiye Zhu, Kangshun Zhu, Rong Liu, Ying–Hong Shi, Yong‐Sheng Xiao, Lan Zhang, Chun Yang, Zhifeng Wu, Zhi Dai, Minshan Chen, Jianqiang Cai, Weilin Wang, Xiujun Cai, Q. Li, Feng Shen, Shukui Qin, Gao‐Jun Teng ほか 2 名 - Liver Cancer 2023 被引用: 452

  10. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hui Zhou, ORIENT-16 Investigators, Hongmei Sun, Qi Wang, Junhe Li, Da Jiang, Weijian Guo, Jieer Ying, Shubin Wang, Aimin Zang, Shirong Cai, Chunhong Hu, Tao Zhang, Min Tao, Jun Liang, Qinsheng Mao, Minghui Zhang, Rui Mao, Hui Yang, Hongyu Zhang, Lin Shen, Jin Lu, Wenxin Li, Yamin Chen, Lei Chen, Zhixiang Zhuang, Chunmei Bai, Heli Liu, Jingtang Chen, Wangjun Liao, Meng Qiu, Rongfeng Song, Man Li, S. B. Qian, Yunpeng Liu, Jiang Liu, Dong Wang, Xianli Yin, Zhiming Huang - JAMA 2023 被引用: 357

  11. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao - The Lancet Oncology 2020 被引用: 584

  12. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 339

  13. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 572

  14. Geographic patterns of co-occurrence network topological features for soil microbiota at continental scale in eastern China

    著者: , , , , , , , , - The ISME Journal 2016 被引用: 1,281

  15. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2019 被引用: 612

  16. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 291

  17. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hua Ye, Weiguo Su - JAMA 2018 被引用: 404

  18. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu - Journal of Clinical Oncology 2016 被引用: 997

  19. Earth microbial co-occurrence network reveals interconnection pattern across microbiomes

    著者: , , , , , , , , , , , - Microbiome 2020 被引用: 578

  20. Long-term care system for older adults in China: policy landscape, challenges, and future prospects

    著者: , , , , , , - The Lancet 2020 被引用: 643

  21. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ting Deng, Yuehong Cui, Jianmin Fang, Yi Ba, Lin Shen - Cancer Communications 2021 被引用: 202

  22. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 816

  23. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Changping Wu, Yang Zhang, Ping Yan, Chunlei Jin, Jianjun Zou - ˜The œLancet. Gastroenterology & hepatology 2021 被引用: 254

  24. AgentCPM-GUI: Building Mobile-Use Agents with Reinforcement Fine-Tuning

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Conference on Empirical Methods in Natural Language Processing: System Demonstrations, EMNLP (System Demonstrations) 2025 被引用: 44